Significant Benefits for Depression, Suicide Risk, and Cardiovascular Health with Vitamin D

From GrassrootsHealth

A new RCT demonstrates that correcting vitamin D deficiency can significantly improve mental health outcomes while simultaneously reducing cardiovascular risk factors

Key Points

In a randomized, placebo-controlled clinical trial of adults with major depressive disorder, weekly vitamin D supplementation (50,000 IU) for six months eliminated vitamin D deficiency and significantly reduced depressive symptoms compared to placebo
Vitamin D supplementation led to a marked reduction in suicide risk, nearly halving the proportion of participants classified as high risk, while suicide risk increased in the placebo group
Participants receiving vitamin D showed significant improvement or normalization in 13 of 15 cardiovascular risk factors, including blood pressure, lipid profiles, insulin resistance, inflammation, arrhythmias, and markers of heart failure
The intervention was safe and well tolerated, with no adverse effects related to calcium metabolism or kidney function, highlighting vitamin D as a low-cost, accessible adjunctive therapy for mental and cardiometabolic health

Depression is not only a leading cause of disability worldwide—it is also closely linked to increased cardiovascular disease risk and higher rates of suicide. In addition, depression is strongly linked to vitamin D, as shown by a large new systematic review of 66 different studies indicating that adults with lower vitamin D levels, especially levels at or below 12 ng/ml, are more likely to have depression.

Meanwhile, a newly published randomized, placebo-controlled, double-blind clinical trial by Porto et al. has demonstrated that correcting vitamin D deficiency can significantly improve mental health outcomes while simultaneously reducing cardiovascular risk factors in adults with major depressive disorder.

About the Trial

Researchers in Northeast Brazil designed the clinical trial to evaluate whether vitamin D supplementation could address the overlapping issues of mental and cardiometabolic vulnerability. The study enrolled 224 adults diagnosed with major depressive disorder, all of whom were receiving standard psychiatric care. Participants were randomly assigned to receive either 50,000 IU of vitamin D per week or a placebo for six months, with outcomes assessed at baseline and at day 180. Researchers measured depressive symptoms, suicide risk, serum vitamin D levels, and a comprehensive panel of cardiovascular risk factors.

Vitamin D Deficiency Was Nearly Universal Yet Fully Correctable

At the start of the trial, more than 80% of participants in both groups were vitamin D deficient. After six months, vitamin D deficiency was eliminated entirely in the supplementation group, while deficiency worsened in the placebo group. Importantly, supplementation raised serum vitamin D into physiological ranges without causing adverse effects related to calcium metabolism or kidney function.

Marked Reductions in Depression Severity and Suicide Risk

Click to Enlarge & Print

Participants receiving vitamin D experienced dramatic improvements in mental health outcomes:

Rates of moderate-to-severe depressive symptoms fell substantially in the vitamin D group (32% decrease), while worsening in the placebo group.
Suicide risk was reduced by nearly half (44% decrease) among those receiving vitamin D, with no corresponding improvement in the placebo group.
No suicide attempts or serious psychiatric adverse events occurred during the intervention.

These findings are consistent with biological evidence that vitamin D functions as a neurosteroid hormone, influencing neurotransmitter synthesis, neuroinflammation, and brain regions involved in mood regulation, as illustrated in the diagram below by Dionisie et al..

Wide-Ranging Improvements in Cardiovascular Risk Factors

Beyond mental health benefits, vitamin D supplementation led to normalization or significant improvement in 13 of 15 cardiovascular risk factors evaluated, including:

Reduced blood pressure and improved hypertension control
Improvements in lipid profiles, including total cholesterol and HDL
Better glycemic control and reduced insulin resistance
Decreased inflammation, reflected by lower C-reactive protein levels
Reductions in left ventricular hypertrophy, arrhythmias, and markers of heart failure

These improvements occurred without changes to psychiatric medications, highlighting vitamin D’s role as a complementary, non-pharmacologic intervention.

This study demonstrated that a weekly oral dose of 50,000 IU of vitamin D for six months was effective and promising among patients with depression, with a reduction in inflammation and improvement in the metabolic profile, contributing to the control of depressive symptoms and proving effective for cardiovascular management.

Why This Matters

The study addressed patients already under psychiatric care who were receiving standard treatments, demonstrating that correcting vitamin D deficiency can meaningfully improve outcomes that medications alone often fail to fully address.

The findings reinforce the importance of measuring and optimizing vitamin D status, particularly in individuals with depression, elevated cardiovascular risk, or suicidal ideation. Given that vitamin D deficiency is both common and correctable, routine testing and personalized supplementation represent one of the most cost-effective, evidence-based interventions available today. Test your vitamin D level and take action today.

SmartTan.com news articles regularly report medical and scientific information to keep you abreast of current events related to UV light. This information is not intended to be used by any party to make unwarranted health claims to promote sunbed usage. Indoor tanning businesses are obligated to communicate a fair and balanced message to all clients about your products and services including the potential risks associated with indoor tanning. Contact your Smart Tan representative to find out more about what you can and can’t say in your tanning salon business.